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Available online 17 February 2016Background: The current riskmodel for percutaneous coronary intervention (PCI) in the UK is based on outcomes
of patients treated in a different era of interventional cardiology. This study aimed to create a newmodel, based
on a contemporary cohort of PCI treated patients, which would: predict 30 daymortality; provide good discrim-
ination; and be well calibrated across a broad risk-spectrum.
Methods and results: The model was derived from a training dataset of 336,433 PCI cases carried out between
2007 and 2011 in England and Wales, with 30 day mortality provided by record linkage. Candidate variables
were selected on the basis of clinical consensus and data quality. Procedures in 2012 were used to perform tem-
poral validation of themodel. The strongest predictors of 30-daymortalitywere: cardiogenic shock; dialysis; and
the indication for PCI and the degree of urgency with which it was performed. The model had an area under the
receiver operator characteristic curve of 0.85 on the training data and 0.86 on validation. Calibration plots indi-
cated a good model ﬁt on development which was maintained on validation.
Conclusion:We have created a contemporary model for PCI that encompasses a range of clinical risk, from stable
elective PCI to emergency primary PCI and cardiogenic shock. The model is easy to apply and based on data re-
ported in national registries. It has a high degree of discrimination and iswell calibrated across the risk spectrum.
The examination of key outcomes in PCI audit can be improved with this risk-adjusted model.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Risk factors1. Introduction
In the UK National Health Service (NHS), efforts to improve the out-
comes of coronary revascularisation have received coordinated atten-
tion since March 2000 [1]. More recently, the outcomes for units, and
now clinicians, have been published —starting with ten surgicaling characteristic curve; BCIS,
tricular ejection fraction; NHS,
; NICOR, National Institute for
West Quality Improvement
of Manchester, M13 9PL, UK.
. Sperrin).
eliability and freedom from bias
land Ltd. This is an open access articldomains as part of the “candour” agenda of opening up NHS perfor-
mance data to public scrutiny [2].
The British Cardiovascular Intervention Society (BCIS, www.bcis.org.
uk) is the professional body representing all those involved in the ﬁeld
of interventional cardiology. Since 2005, BCIS has incorporated patient-
level data in its long running annual audit of all percutaneous coronary
intervention (PCI) procedures performed in the UK. This audit is used
for benchmarking performance to help improve services and underpin
clinical governance [3]. Due to wide variations in case mix between
both operators and PCI centres, crude mortality metrics cannot be
used to compare clinical and procedural outcomes. Using index cases
to compare outcomes for patients with more homogenous clinical fea-
tures has several limitations. The preferred approach is to use risk-
adjustment techniques that take into account the variability of expected
outcomes for patients who present with different combinations of risk
factors [4].e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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has been used for risk-adjusted outcome surveillance since 2006 [5].
This model was developed from data on patients treated in North
West of England between 2001 and 2003. Since then there have been
major changes in PCI techniques, adjunctive therapies, and in clinical in-
dications for PCI. In 2003 themainstay of treatment for patients with ST
elevation myocardial infarction (MI) was thrombolysis, but by 2012,
over 93% of patients were treated with primary PCI [6]. The NWQIP
model has been used over this time to adjust for case-mix when
auditing the outcomes of PCI. Since the NWQIP model was developed,
more than a decade ago, there have been changes in case-mix and clin-
ical practise, most signiﬁcantly the systematic uptake of primary PCI.
Evaluation in a contemporary cohort from the BCIS dataset suggests
that while the model retains reasonable overall discrimination for
major adverse cerebrovascular or cardiovascular events (MACCEs) it
has been subject to signiﬁcant calibration drift with consistent over-
prediction of risk (see Supplementary materials). This inaccuracy de-
mands a new model based on contemporary data. For UK national
audit purposes both the data and models need quality assurance. The
quality of current adverse event reporting depends on local practises
at PCI centres. In this regard, in spite of a series of internal validation
checks on data consistency, there are substantial variations in the qual-
ity of the audit data returned by different centres [7].
The aim of this study was to produce an updated robust risk adjust-
ment model with good discrimination and correct calibration for
contemporary PCI practise in the UK. A similar updating exercise has re-
cently been undertaken in the National Cardiovascular Data Registry in
the US [8]. We chose to assess 30 day mortality rather than in-hospital
major adverse cerebrovascular or cardiovascular event because the for-
mer can be derived from linkage with the Ofﬁce for National Statistics
records (a consistent end point that is not inﬂuenced by local variation
in data completeness). We excluded patients suffering a cardiac arrest
and being treated outside of hospital prior to PCI because this group
contains a heterogeneous combination of patients with different risk
proﬁles, and also because of concerns that including such patients
might lead to inappropriately risk-averse clinical behaviour [9].2. Material and methods
2.1. Deﬁnition of dataset and pre-processing
The BCIS database comprises 113 variables describing baseline
demographics, clinical presentation, procedural details and outcomes
to hospital discharge. Data for all procedures performed in the UK are
collected at each PCI centre, encrypted and then uploaded to servers
now hosted by the National Institute for Clinical Outcomes Research
(NICOR) based at University College London [3]. The Ofﬁce for
National Statistics provides reliable independent tracking of mortality
(for patients living in England and Wales only), using linkage by each
patient's unique identiﬁer. Cases in Scotland and Northern Ireland
were therefore excluded from the model development. Linkage was
carried out by the Medical Research Information Service on behalf of
NICOR. Analysis was conducted at the University of Manchester
with Local Research Ethics Committee approval (reference no.11/
NW/0694). The data were cleaned and analysed using Stata® MP
v11.2 (StataCorp LP).
Although there is no independent validation of data entry, a number
of range checks and assessments of internal validity are applied as data
are uploaded to NICOR.We performed a sequence of further procedures
to clean the dataset. A number of exclusion criteriawere applied (Fig. 1).
We limited our analysis to patients aged over 18 and under 100 at the
time of procedure. Patients outside of these age limits are small in
number, but could contribute disproportionately to outcomes. Patients
without tracked mortality data were also excluded (this excluded
group incorporating all patients from Scotland and Northern Ireland).Patients who were ventilated before PCI were also excluded, this ﬁeld
being used as a proxy indicator for out of hospital cardiac arrest.
A total of 1112 procedures were identiﬁed as likely duplicate entries
and were also excluded. These were identiﬁed by comparing records
across age, gender, pseudonymised hospital identiﬁer, pseudonymised
patient identiﬁer, pseudonymised date of operation, month of opera-
tion, time of operation, urgency, clinical indication for procedure and
status at discharge. Data used for the ﬁnal model are available from
the authors where the requester has sought permission from NICOR.
2.2. Variable selection and deﬁnition
Of the available ﬁelds in the BCIS dataset, a shortlist of 10 candi-
date risk factors was identiﬁed by the authors on the basis of clinical
consensus and data quality. As the model was intended to be used to
predict outcome before the start of a procedure, variables relating to
decisions or events occurring during or after the procedure were
excluded.
Age at procedure was given in years and months. For modelling,
age was mean-centred within the development cohort (mean =
64.8 years); a quadratic age term was also explored. Diabetes was
deﬁned as present whether patients were diet controlled, or treated
with medication including insulin. Serum creatinine levels were only
recently added to the dataset and were therefore missing in earlier
years of the development cohort. However, a binary variable indicat-
ing whether creatinine measures were greater than 200 μmol/l was
available throughout the time period, so this was used as the mea-
sure of renal function. Use of dialysis for acute or chronic renal failure
was also recorded, and if both this and a creatinine measure of
N200 μmol/l were present, the patient was assigned to the ‘dialysis’
group. Patients with functioning transplants were grouped with
those who had no renal impairment, unless on dialysis or with a cre-
atinine N200 μmol/l.
Deﬁnitions of the ﬁelds are available online (www.ucl.ac.uk/nicor/
audits/adultpercutaneous/datasets). Clinical indication for PCI proce-
dure is recorded as one of 12 possible options in the database. For the
purposes of this model we derived a simpler ﬁve-group classiﬁcation
to combine the clinical indication and the urgency of the procedure, to
avoid the problem of collinearity between these two variables. These
groups are described in Table 1.
Therewere insufﬁcient data available on ethnicity of patients to con-
sider this as a variable in themodel.Wedid not include ameasure of left
ventricular ejection fraction as data on this characteristic were missing
in 50.7% of all patients, and in 67.4% of emergency or salvage patients.
Furthermore, not only is LV function rarely known at the time of emer-
gency PCI for STEMI, but also can be labile following intervention. Sen-
sitivity analysis was conducted to evaluate alternative modelling
strategies which would enable the inclusion of this risk factor; ﬁrstly
in a model trained only on cases where data on this risk factor were
available, and secondly on a fully multiply-imputed training dataset.
2.3. Missing data handling
The percentage of data missing in the shortlisted variables is shown
in Table 2. Before excluding patients aged over 100, in cases where age
at procedure was recorded as greater than 120 years this was assumed
to be erroneous and re-coded as missing. Missing age values in the de-
velopment cohort were replaced with the median by gender within
that cohort (males 63.6 years, females, 69.6 years). The same values
were used to replace missing age values in the training cohort, as it
was assumed that during model use the median population ages
might not be available. For categorical variables, missing values were
assigned to the baseline category i.e. it was assumed that if a risk factor
was not recorded then it was absent. This represents a plausiblemissing
not at randommechanism that is likely to operate in this case (multiple
imputation assumes that data are missing at random), and incentivises
Fig. 1. Flow chart illustrating creation of analysis and validation dataset from the available records in the BCIS database.
Table 1
Groupings of BCIS ﬁeld entries for clinical indication for procedure, to give a ﬁve-group
classiﬁcation of procedural type and urgency.
Group Indication/urgency
1 “Stable — angina” OR
“Stable — coronary/LV anatomy” OR
“Staged procedure” OR
“Hybrid procedure”
2 “ACS — UA, NSTEMI or convalescent STEMI” AND “urgent”
3 “ACS — UA, NSTEMI or convalescent STEMI” AND “emergency” OR
“ACS — UA, NSTEMI or convalescent STEMI” AND “salvage”
4 “ACS — primary PCI for STEMI (no lysis)” OR
“ACS — facilitated PCI for STEMI (lysis + PCI)” OR
“Acute or sub-acute PCI thrombosis” OR
“Bail out following acute complication of diagnostic cardiac catheterisation”
5 “ACS — rescue PCI for STEMI (failed lysis)” OR
“ACS — PCI for re-infarction (no lysis)” OR
“ACS — rescue PCI for re-infarction (failed lysis)”
ACS = acute coronary syndrome; LV= Left ventricular; UA= unstable angina; NSTEMI =
non-ST elevated myocardial infarction; STEMI = ST elevated myocardial infarction.
Table 2
Frequency and % of missing data for each variable included in the model.
Training data
(2007–2011);
n = 336,433
Validation data
(2012);
n = 76,804
Variable n missing % missing n missing % missing
Age at procedure 166 0.05 9 0.01
Gender 754 0.22 90 0.12
Diabetes 13,998 4.16 4144 5.40
Urgency of procedure 361 0.11 105 0.14
Previous CABG 16,716 4.97 1763 2.30
Previous MI 38,956 11.58 5702 7.42
Renal disease 18,608 5.53 3349 4.36
Indication for intervention 5831 1.73 233 0.30
History of cerebrovascular event 146 0.04 42 0.05
Cardiogenic shock 24,269 7.21 3593 4.68
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by the Society for Cardiothoracic Surgery [10]. A sensitivity analysis to
assess the suitability and potential beneﬁt of usingmultiple imputations
was also conducted (see Supplementary materials).2.4. Model development and validation
An iterative clinical and stepwise logistic regression modelling ap-
proach was used. The statistically automated selection of independent
variables was based on backward-elimination via the Akaike informa-
tion criterion, aiming to optimise model ﬁt. Clinical opinion was sought
and further reﬁnement of the candidate variable list wasmade, and fur-
ther modelling was carried out, until we developed a model which was
both clinically and statistically robust.
We examined the goodness of ﬁt (calibration) and the ability of
the model to correctly separate those who went on to have the out-
come from those who did not (discrimination). We used visual in-
spection of calibration plots derived from calculating the Hosmer–
Lemeshow statistic, as opposed to relying on P values for this statis-
tic, which are often unreliable with large datasets [11]. For assessing
discrimination we used the c-statistic, which corresponds to the area
under the receiver operating characteristic curve (AUC). The higher
the value of the AUC, the better the model discriminates between
true positive predictions and true negative predictions. An AUC of
0.5 would indicate a model which is no better at predicting the out-
come than a random coin toss. In the cardiovascular disease and out-
come risk prediction literature, reported AUCs are typically in the
range of 0.7 to 0.95.
To improve the calibration of the model, we also explored interac-
tion terms. A selection of clinically plausible interactions was tested by
introducing them individually into the model. Those which gave a sta-
tistically signiﬁcant contribution to the model were then introduced in
a forward stepwise manner with manual selection on the basis ofTable 3
Patient characteristics and crude mortality rates (%) for each variable in the training and valida
Training dataset
Alive (n = 330,7
n %
Gender Male 245,884 98.5
Female 84,827 97.6
Diabetic No 272,427 98.4
Yes (diet controlled, oral Rx, insulin) 58,284 97.7
Urgency Elective 139,894 99.6
Urgent 118,416 98.7
Emergency 71,834 95.2
Salvage 567 82.8
Previous CABG No 303,359 98.2
Yes 27,352 98.6
Previous MI No 247,273 98.3
Yes 83,438 98.2
Previous PCI No 247,462 98.1
Yes 68,611 98.8
Renal disease/dysfunction None 323,822 98.4
Creatinine N200 μmol/l 4481 92.8
Dialysis 2408 94.2
Indication Stable 142,330 99.5
Acute, not primary 124,665 98.5
Acute, primary 62,870 95.1
Other 846 92.7
History of cerebrovascular event No 318,867 98.3
Yes 11,844 96.0
Cardiogenic shock No 327,392 98.6
Yes 3319 70.6
Age Mean age at procedure 64.6 (95% CI 64.6
64.7)
Median age at procedure 64.9 (IQR 17)
P values indicate results of statistical comparisons within datasets of patients recorded alive vsAkaike information criterion. In the interests of maintaining parsimony,
we restricted the number of interaction terms to three.
The selected model was then validated on data from 2012 (n =
76,804) and calibration and discrimination tests were performed as
above.
3. Results
3.1. Model development
Of the 336,443 procedures included in the model development
dataset from 2007 to 2011, a total of 5722 patients died within
30 days of their procedure (1.7%). Table 3 displays the percentage of pa-
tients with each risk factor who were either alive or dead within
30 days; all risk factors except previous myocardial infarction were
found to be statistically signiﬁcantly associated with the outcome
using a threshold of P b 0.05. In particular, the crude 30-day mortality
in patients who experienced cardiogenic shock was 29.3% compared
with 1.3% in those who did not; 7.2% of patients with creatinine
N200 μmol/l and 5.7% of patients on dialysis died compared to 1.6%
with no renal impairment. Mortality was higher in patients whose pro-
cedurewas classiﬁed as emergency (4.8%) or salvage (17.1%) than those
whose procedure was elective (0.4%) or urgent (1.3%); salvage proce-
dures being those undertaken in the context of a patient being resusci-
tated en route to the catheter laboratory. Similarly,mortalitywas higher
in patients with an acute primary PCI (4.9%) or acute non-primary PCI
indication (1.5%) than a stable clinical indication (0.4%).
The ﬁnal model is shown in Table 4. There were nine independent
risk factors in the model, all with a statistically highly signiﬁcant
(P b 0.001) contribution: mean-centred age, female gender, diabetes,
previousmyocardial infarction, renal disease, history of cerebrovascular
event, clinical indication/urgency, and cardiogenic shock. Cardiogenic
shock provided the largest categorical variable coefﬁcient in the model
of 3.82 (95% CI 3.43 to 4.21); this means risk of mortality is highertion datasets.
(2007–2011) Validation dataset (2012)
11) Dead (n = 5722) Alive (n = 75,234) Dead (n = 1570)
n % P n % n % P
2 3701 1.48 b0.001 55,945 98.33 952 1.67 b0.001
7 2021 2.33 19,289 96.90 618 3.10
3 4354 1.57 b0.001 60,847 98.13 1161 1.87 b0.001
1 1368 2.29 14,387 97.24 409 2.76
4 501 0.36 b0.001 27,220 99.68 88 0.32 b0.001
5 1499 1.25 26,196 98.71 342 1.29
2 3605 4.78 21,774 95.13 1115 4.87
9 117 17.11 44 63.77 25 36.23
7 5335 1.73 b0.001 69,169 97.91 1476 2.09 0.003
0 387 1.40 6065 98.47 94 1.53
2 4222 1.68 0.089 57,124 97.98 1179 2.02 b0.001
3 1500 1.77 18,110 97.89 391 2.11
9 4568 1.81 b0.001 56,075 97.79 1270 2.21 b0.001
2 821 1.18 17,202 98.69 228 1.31
1 5231 1.59 b0.001 73,475 98.08 1439 1.92 b0.001
5 345 7.15 1177 93.12 87 6.88
8 146 5.72 582 92.97 44 7.03
9 587 0.41 b0.001 27,383 99.67 90 0.33 b0.001
3 1861 1.47 27,727 98.39 453 1.61
5 3208 4.85 19,929 95.17 1011 4.83
6 66 7.24 195 92.42 16 7.58
9 5234 1.61 b0.001 72,326 98.07 1423 1.93 b0.001
4 488 3.96 2908 95.19 147 4.81
9 4345 1.31 b0.001 74,372 98.45 1171 1.55 b0.001
8 1377 29.32 862 68.36 399 31.64
to 73.3 (95% CI 73.0
to 73.6)
b0.001 64.9 (95% CI 64.8 to
64.9)
74.3 (95% CI 73.7
to 74.8)
b0.001
75 (IQR 16) 65 (IQR 18) 76 (IQR 16)
dead at 30 days (Chi squared test for categorical variables, t test for age).
Table 4
The ﬁnal logistic regression model.
Coefﬁcient
- log odds
Odds
ratio
Odds
ratio
Lower CI
bound
Odds
ratio
Upper CI
bound
p
Centred age 0.071 1.073 1.069 1.077 b0.001
Female sex 0.114 1.121 1.056 1.190 b0.001
Diabetes 0.524 1.689 1.557 1.831 b0.001
Previous MI 0.158 1.171 1.097 1.251 b0.001
Renal disease
Creatinine 0.997 2.708 2.378 3.087 b0.001
Dialysis 1.128 3.090 2.557 3.735 b0.001
Cerebrovascular event 0.430 1.537 1.385 1.706 b0.001
Indication-urgency
Group 2 1.004 2.729 2.470 3.014 b0.001
Group 3 2.114 8.283 7.126 9.629 b0.001
Group 4 2.295 9.921 9.013 10.921 b0.001
Group 5 2.531 12.561 10.788 14.656 b0.001
Cardiogenic shock 3.817 45.473 30.721 67.309 b0.001
Age-shock interaction −0.026 0.975 0.968 0.982 b0.001
Indication-shock
interaction
Group 2 −0.951 0.386 0.246 0.605 b0.001
Group 3 −1.226 0.294 0.185 0.465 b0.001
Group 4 −1.203 0.300 0.201 0.449 b0.001
Group 5 −1.438 0.237 0.149 0.377 b0.001
Age-diabetes interaction −0.016 0.984 0.977 0.990 b0.001
Constant/intercept −6.089 0.002 0.002 0.003 b0.001
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weighted heavily in the model with a coefﬁcient of 2.53 (95% CI 2.38
to 2.68) for the highest risk category (group 5) as were dialysis (coefﬁ-
cient 1.13, 95% CI 0.94 to 1.32) and creatinine N200 μmol/l (coefﬁcient
1.00, 95% CI 0.87 to 1.13).
There were three interaction terms introduced to improve the cali-
bration of the model: clinical indication and cardiogenic shock, centred
age and cardiogenic shock and centred age and diabetes. The negative
coefﬁcients associated with these interactions effectively correct for
over estimation of risk in patients who have both risk factors in the in-
teraction pair. The quadratic term for age did not improve the model
so it was not included.
Risk prediction is carried out by summing constant and all coefﬁ-
cients where a risk factor is present to derive the log odds. 64.8 is
subtracted from age before multiplying by coefﬁcient. Interaction coef-
ﬁcients are used when both interacting features are present.
For example, a 75-year old male with diabetes, in urgency group 2
would have log-odds = −6.089 + 0.071*(75–64.8) + 0.524 +
1.004 + (−0.016) × (75–64.8) =−4.000. This can be converted to a
probability: P = 100/(1 + exp.(−(−4.000))) = 1.80%.
3.2. Model validation
The validation data from 2012 comprised 75,234 procedures with a
30 day mortality of 2.09%. The validation cohort was similar to the de-
velopment cohort in terms of patient characteristics though patients
in the validation cohort were on average slightly older (mean age
alive = 64.9, mean age dead = 74.3) and a far higher percentage of
the patients who diedwithin 30 days had been classiﬁed as salvage pro-
cedures (36.2% compared with 17.1% in the development cohort).
Fig. 2 illustrates the calibration and discrimination of the model in
both development and on validation. In development, the model dis-
crimination was good, represented by an AUC of 0.848. On validation
the discrimination was maintained at a similar level, with an AUC of
0.859. This represents discriminative ability at the upper end of the
range of models in this clinical domain.
Calibration plots at a range of quantile thresholds indicated a good
model ﬁt with the development data. Fig. 2(iii)shows the calibration
plot for 100 risk strata. With the development cohort data thecalibration plots were slightly less good, but still acceptable: Fig. 2(iv).
To assess the validity of using a single model in spite of a wide range
of predicted risk, we assessed its calibration and goodness of ﬁt in the
subset of patients being treated for ST elevated myocardial infarction
by primary PCI and also on the subset being treated for stable angina
and non-ST elevatedmyocardial infarction. In both subsets it performed
well with AUCs of 0.822 and 0.818 respectively.
3.3. Sensitivity analysis
We examined different approaches to handling missing data. Com-
plete case analysis was performed by examining the performance of
the above model only in people who had information available for all
the included variables (see Supplementary materials). Of the develop-
ment cohort, 264,053 (78.5%) of people fulﬁlled this criterion. The
model coefﬁcients and intercept were broadly similar. There was an in-
crease in the coefﬁcient for indication-urgency group 5 but a decrease in
the coefﬁcient for cardiogenic shock. The area under the ROC curve for
the complete case model was 0.789. This drop in model discrimination
may lend support for the inclusion of non-complete cases under an im-
putation framework.
Multiple imputation was conducted as a sensitivity analysis to see if
there was any additional beneﬁt in using this approach. Overall the
model coefﬁcients remained broadly consistent undermultiple imputa-
tion, though the coefﬁcient for cardiogenic shockdecreased from3.82 to
3.73 (with a corresponding drop in odds ratio of 45.47 to 41.76). There
was no difference in the AUC between ‘missing assumed absent’ and
multiple imputation, as assessed using either the training or validation
datasets, nor did calibration plots noticeably differ.
Inclusion of LVEF as a variable in the model under different missing
data handling frameworks identiﬁed thatworsening LVEFwas associat-
ed with a higher odds of 30 day mortality. However, the estimated size
of the effect was sensitive to the method used. When the model was
trained only on cases where LVEF data were present, ‘fair’ LVEF (30–
50%) was assigned a coefﬁcient of 0.84 (OR 2.31, 95% CI 2.08–2.56,
P b 0.001) and ‘poor’ LVEF (b30%) had a coefﬁcient of 1.67 (OR 5.31,
95% CI 4.72–5.97, P b 0.001). Where multiple imputation was used,
however, the estimates shrunk: fair LVEF gave 0.28 (OR 1.33, 95% CI
1.23–1.44, P b 0.001) and poor LVEF gave 0.79 (OR 2.19, 95% CI 2.02–
2.39, P b 0.001). A comparison of models where LVEFwas orwas not in-
cluded indicated only a small incremental improvement in overall
model discrimination on its inclusion: in the full training set a model
without LVEF had an AUC of 0.848 while a model with LVEF had an
AUC of 0.852. We decided not to include LV function in our model for
a number of reasons. We wanted the model to be as parsimonious as
possible. The analysis above has shown only a small improvement in
AUC. Our model needed to be as robust as possible in the setting of a
National data collection programme, where the majority of PCI is per-
formed in an acute setting, the likelihood of a signiﬁcant improvement
in data collection for LV functionwas low in the short term, and the var-
iability of LV function in this setting acknowledged but poorly deﬁned.
4. Discussion
4.1. Summary
We have created a contemporary PCI mortality model that en-
compasses a wide range of clinical risk, from stable elective PCI to
emergency primary PCI and cardiogenic shock. It has a high degree
of discrimination and is well calibrated across the risk spectrum.
The overriding aim of clinical audit is to drive up standards of care.
This requires that important aspects of care are measured so they can
be assessed. Robust risk adjustment underpins any clinical audit that
is used to assess institutional or individual operator performance.
There are several outcomes by which the quality of PCI might be
measured. While symptom relief is undoubtedly important in patients
Fig. 2. Illustrations of model discrimination and calibration. (i) Receiver operating characteristic curve of model on development data (2007–2011), (ii) receiver operating characteristic
curve of model when applied to validation data (2012), (iii) calibration plot 100 quantiles) for model in development, and (iv) calibration plot (100 quantiles) for model on validation.
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text of an acute coronary syndrome [7], for which mortality is the least
biased and arguably the most important outcomemeasure. In addition,
any national audit is limited by logistic and funding issues. Our experi-
ence is that the completeness and accuracy of self-reported outcomes
vary considerably. Our pragmatic solution was to use the Ofﬁce for
National Statistics tracked mortality as an outcome because it is inde-
pendent of local data collection heterogeneity.
4.2. Comparison with other models
The model presented here represents a tool which better reﬂects
contemporary UK clinical practise than existing published models. The
previous UKNWQIPmodel [5] reﬂected practise before the era of wide-
spread uptake of primary PCI, was found to be poorly calibrated in the
assessment of contemporary procedures and therefore a new model
was required. The new BCIS model does demonstrate some consistency
with the previousmodel, despite the differences in outcome and patient
population: in both models cardiogenic shock and degree of urgency of
the procedure are heavily weighted. There are, however, several differ-
ences. We have opted to consider age as a continuous variable so as to
introduce ﬁner granularity of risk assessment in this variable. The BCIS
model now includes a measure of renal function, while omitting vari-
ables relating to the lesions treated. In the latter case this was due to a
priori decision to exclude variables relating to the peri-procedural
period; this is pertinent to themodel's intended use for appraisal of op-
erator performance, as such variables may be inﬂuenced by operator’s
decisions. In keeping with the NWQIP model, we have opted to retain
the regression model weights rather than derive an integer-based
score, as the latter is an anachronism of pre-computer clinicalprediction. We include a measure of renal function, even though this
may not be known at the time of emergency procedures as we wanted
to restrict the model to risk factors present prior to procedure, whether
knownor not at the timeof treatment. This is appropriate, given that the
primary intended purpose of the model is service audit, rather than
aiding pre-procedural clinical decisions.
It is possible that the discrimination of this model would improve
with the addition of further risk factors. Lack of sufﬁcient data on left
ventricular ejection fraction (LVEF) was a notable limitation of our
data resource. The Toronto PCI in-hospital mortality score, which has
an AUC of 0.96, incorporates a binary measure of LVEF, assigning an
odds ratio of 1.40 to patients with LVEF of b20% [12]. Both this model
and the US National Cardiovascular Disease registry in-hospital mortal-
itymodel (AUC of 0.93) [8] incorporatedmeasures of estimated glomer-
ular ﬁltration rate into models, rather than using a binary creatinine
threshold as we have done here. It is intended that in future updates
to the BCIS model, we will consider estimated glomerular ﬁltration
rate for incorporation, as improved collection of data on these risk fac-
tors is mandated in future data collection. Left ventricular function
was not included in the model as this was missing in 50.7% of cases.
Additional reasons have been discussed above but inclusion did not
add usefully to AUC.
4.3. Using risk models in clinical practise
Clinical performance measurement is moving into an era of greater
openness, transparency and candour. It is no longer acceptable for
measures of outcome to be used only within professional bodies. Public
reporting of outcomes of individual operators is intended to drive up
standards, and uncloak what has been perceived as professional secrecy.
131K.S.L. McAllister et al. / International Journal of Cardiology 210 (2016) 125–132In providing patientswithmuchmore information, it aims to help a ratio-
nal selection of treatment choices, and to promote a better understanding
of expected outcomes. It demonstrates to the public that quality of care is
being actively monitored and improved where necessary. Public
reporting also encourages healthcare organisations to focus on recording
and providing more complete and accurate information.
An important problemwith public reporting is that it can precipitate
risk-averse clinical decisions, disadvantaging the sickest patients
who have the most to beneﬁt from interventions [13–16]. If a model
under-predicts risk in high risk cases, then a cardiologist taking on
these cases may be incorrectly assessed to be underperforming, and
recognising this will be anxious to avoid treating such patients. In the
UK, cardiothoracic surgeons have been reporting outcome data for
some years [17]. In a recent analysis of the performance of EuroSCORE
II they demonstrated that it was poorly calibrated and had weak dis-
crimination for emergency cardiac surgery [18]. As a result such cases
are currently excluded from reports. It is therefore critically important
that themodel we have created performswell at extremes of risk. How-
ever, in the setting of out of hospital cardiac arrest no satisfactory risk
model currently exists, and to reduce the potential harm from risk-
averse clinical behaviour over patients presenting in thisway,we decid-
ed to exclude them both from this model, and from public reporting of
PCI outcomes in the UK for the time being [9].
4.4. Limitations
Although the BCIS audit programme applies to all UK procedures,
the model was ﬁt using only data from England and Wales, since re-
cord linkage via the Ofﬁce for National Statistics is available only for
these patients. This does, however, present opportunity for valida-
tion studies in Scotland and Northern Ireland; these regions may
have different patterns of risk factors and mortality, adding useful
heterogeneity to the extended validation of this model. Further tem-
poral validation should be conducted in future years to ensure the
performance of the model remains acceptable, with recalibration
performed as necessary [19,20].
Our practise of replacing missing categorical values with null values
may lead to biased estimates of individual patient risk. This will cause
bias if some centres or operators are systematically under-reporting
the presence of risk factors. However, we found no beneﬁt to be had
from conducting multiple imputation, and it may be more productive
to focus efforts on reducing missing data at source in future years of
the audit. Given the additional complexity of applying the model in a
multiple imputation framework, and the fact that data may be missing
in patterns other than random, our approach is appropriate at this time.
Due to limitations imposed by the data sharing framework, we did
not have access to un-pseudonymised procedure date. It was therefore
not possible to identify redo procedures (i.e. thosewhichwere a second
attempt),whichmayhave led to somedouble counting of procedures or
potential underestimation of the mortality burden of the index proce-
dure in cases where a patient died following a redo procedure. We
hope that the establishment of “safe havens” for analysis by national or-
ganisations such as the Farr Institutewill enable such analyses in the fu-
ture, better serving patients with proportionate governance of their
information [21].
4.5. Future research
We intend to validate themodel further, andmonitor the calibration
and discrimination performance over time, updating as necessary.
Future updates of the model will likely incorporate established or
emerging risk factors that we were not able to include in this version.
In addition,we are investigating dynamicmodelling approaches that
will run continuous statistical surveillance of model performance and
prompt the clinical audit team over possible calibration drift and poten-
tial structural deterioration of the model. Where factors such as renalfunction are under-represented due to data quality they can be kept
onwatch for fuller inclusion as the data are better collected. In addition,
there is a need to study the effects of different forms of audit feedback
on data collection and quality.
4.6. Conclusions
We have generated a new parsimonious and contemporary model
for predicting risk of 30-day mortality in patients undergoing PCI in
theUK. It shows good discrimination and calibration across awide spec-
trum of risk. It takes into account the marked changes to the perfor-
mance of PCI in recent years and is independent of variations in
completeness of adverse event reporting and therefore is amore appro-
priate choice of model for the BCIS national audit programme.
Disclosures
The authors report no relationships that could be construed as a con-
ﬂict of interest.
Acknowledgements
PFL, MAdB and IEB conceived the study. KSLM undertook the prima-
ry analysis and drafted the manuscript and WH conducted additional
analyses, MS and IEB provided statistical input; and MAdB, RS, PFL,
MAM and SC provided clinical input; in the selection and interpretation
of the ﬁnal model. All authors reviewed and edited the manuscript for
intellectual content and have read and approved the ﬁnal version.
This work was supported by the Medical Research Council [MR/
K006665/1]. KSLM was funded by an NIHR-CLAHRC studentship.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2016.02.085.
References
[1] Department of Health, National Service Framework for Coronary Heart Disease,
2000.
[2] National Health Service, 2013/14 NHS Standard Contract: Technical Contract Guid-
ance, 2013.
[3] P. Ludman, British Cardiovascular Intervention Society Registry for audit and quality
assessment of percutaneous coronary interventions in the United Kingdom, Heart
97 (2011) 1293–1297.
[4] K.J. Rothman, S. Greenland, T.L. Lash, Modern Epidemiology, Lippincott Williams &
Wilkins, 2008.
[5] A.D. Grayson, R.K. Moore, M. Jackson, S. Rathore, S. Sastry, T.P. Gray, et al., Multivar-
iate prediction of major adverse cardiac events after 9914 percutaneous coronary
interventions in the north west of England, Heart 92 (2006) 658–663.
[6] J.M. Mclenachan, H.H. Gray, M.A. De Belder, P.F. Ludman, D. Cunningham, J.
Birkhead, Developing primary PCI as a national reperfusion strategy for patients
with ST-elevation myocardial infarction: the UK experience, EuroIntervention 8
(2012) 99–107.
[7] P.F. Ludman, Audit of Adult Intervention in 2012, 2013.
[8] J.M. Brennan, J.P. Curtis, D. Dai, S. Fitzgerald, A.K. Khandelwal, J.A. Spertus, et al., En-
hanced mortality risk prediction with a focus on high-risk percutaneous coronary
intervention: results from 1,208,137 procedures in the NCDR (National Cardiovas-
cular Data Registry), JACC Cardiovasc. Interv. 6 (2013) 790–799.
[9] M.A. Peberdy, M.W. Donnino, C.W. Callaway, J.M. Dimaio, R.G. Geocadin, C.A.
Ghaemmaghami, et al., Impact of percutaneous coronary intervention performance
reporting on cardiac resuscitation centers: a scientiﬁc statement from the American
Heart Association, Circulation 128 (2013) 762–773.
[10] G.L. Hickey, S.W. Grant, R. Cosgriff, I. Dimarakis, D. Pagano, A.P. Kappetein, et al.,
Clinical registries: governance, management, analysis and applications, Eur. J.
Cardiothorac. Surg. 44 (2013) 605–614.
[11] J.P. Marcin, P.S. Romano, Size matters to a model's ﬁt, Crit. Care Med. 35 (2007)
2212–2213.
[12] S. Chowdhary, J. Ivanov, K. Mackie, P.H. Seidelin, V. Dzavík, The Toronto score for in-
hospital mortality after percutaneous coronary interventions, Am. Heart J. 157
(2009) 156–163.
[13] M. Moscucci, K.A. Eagle, D. Share, D. Smith, A.C. De Franco,M. O'Donnell, et al., Public
reporting and case selection for percutaneous coronary interventions: an analysis
from two large multicenter percutaneous coronary intervention databases, J. Am.
Coll. Cardiol. 45 (2005) 1759–1765.
132 K.S.L. McAllister et al. / International Journal of Cardiology 210 (2016) 125–132[14] J.M. McCabe, K.E. Joynt, F.G.P. Welt, F.S. Resnic, Impact of public reporting and
outlier status identiﬁcation on percutaneous coronary intervention case selec-
tion in Massachusetts, JACC Cardiovasc. Interv. 6 (2013) 625–630.
[15] K.E. Joynt, D.M. Blumenthal, E.J. Orav, F.S. Resnic, A.K. Jha, Association of public
reporting for percutaneous coronary intervention with utilization and outcomes
among Medicare beneﬁciaries with acute myocardial infarction, JAMA 308 (2012)
1460–1468.
[16] R. Apolito, M. Greenberg, M. Menegus, A.M. Lowe, L. Sleeper, M.H. Goldberger, et al.,
Impact of the New York state cardiac surgery and percutaneous coronary interven-
tion reporting system on the management of patients with acute myocardial infarc-
tion complicated by cardiogenic shock, Am. Heart J. 155 (2008) 267–273.
[17] Society for Cardiothoracic Surgery in Great Britain & Ireland, Blue Book Online, Soc.
Cardiothorac. Surg. Gt. Britain Irel., 2013 (http://bluebook.scts.org/).[18] S.W. Grant, G.L. Hickey, I. Dimarakis, G. Cooper, D.P. Jenkins, R. Uppal, et al., Perfor-
mance of the EuroSCORE models in emergency cardiac surgery, Circ. Cardiovasc.
Qual. Outcomes 6 (2013) 178–185.
[19] K. Van Hoorde, Y. Vergouwe, D. Timmerman, S. Van Huffel, E.W. Steyerberg, B. Van
Calster, Assessing calibration of multinomial risk prediction models, Stat. Med. 33
(2014) 2585–2596.
[20] K.J.M. Janssen, K.G.M. Moons, C.J. Kalkman, D.E. Grobbee, Y. Vergouwe, Updating
methods improved the performance of a clinical prediction model in new patients,
J. Clin. Epidemiol. 61 (2008) 76–86.
[21] Department of Health, Protecting Health and Care Information: A Consultation on
Proposals to Introduce New Regulations, 2014.
